Hydrolyzed Collagen in the Reduction of Osteoarticular Pain and Functional Limitation
Launched by FRANCISCO JOSE RODRIGUEZ VELASCO · Nov 25, 2021
Trial Information
Current as of September 14, 2025
Completed
Keywords
ClinConnect Summary
In recent years, research efforts have focused on interventions such as collagen supplementation as an alternative treatment for pain and physical function in patients with osteoarthritis. Hydrolyzed collagen (HC) is a mixture of collagen peptides with a molecular weight of less than 5,000 Da. It is obtained from the gelatinization and subsequent enzymatic hydrolysis of native collagen from animal tissues rich in this protein. In this line, several studies show that HC is more easily absorbed enzymatically, has a higher bioavailability, is distributed to joint tissues, and has analgesic and...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of osteoarthritis according to the clinical and radiographic criteria of the American College of Rheumatology.
- • Pain score of at a minimum of 50 mm on a VAS scale of 0-100 mm
- Exclusion Criteria:
- • Presence of a previous cardiovascular event in the last 6 months.
- • History of liver or kidney disease.
- • Presence of medical condition requiring chronic treatment with drugs or other substances.
- • Excessive alcohol consumption (\> 20 g/day) or substance abuse.
- • Presence of intolerance or hypersensitivity to the food supplement or to any of its components in isolation.
- • Use of any intra-articular injection in the anatomical area under study in the last 6 months.
- • Treatment with symptomatic slow-acting osteoarthritis drugs (SYSADOA) in the last 3 months.
- • Criteria listed in the Clinical Investigation Guideline for medicinal products used in the treatment of osteoarthritis published by the European Medicines Agency of the European Union in 2010 and radiographic osteoarthritis grade 4 according to the Kellgren-Lawrence classification system.
- • Any condition that, in the opinion of the investigators, would disqualify the subject from participation in the study.
About Francisco Jose Rodriguez Velasco
Francisco Jose Rodriguez Velasco is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes. With a focus on innovative therapeutic solutions, he oversees the design, implementation, and management of clinical trials, ensuring compliance with regulatory standards and ethical guidelines. His extensive expertise in clinical research, combined with a passion for enhancing healthcare, drives the pursuit of high-quality data that supports the development of safe and effective treatments. Through strategic collaboration with healthcare professionals and research institutions, Rodriguez Velasco aims to contribute significantly to the scientific community and the advancement of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Barcelona, Spain
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials